Head of Dengvaxia study admits she has relative in Sanofi

Jamaine Punzalan, ABS-CBN News

<figure class='op-interactive'><iframe height='315' src='https://www.youtube.com/embed/RU7FdPYTNyk?enablejsapi=1' width='560'></iframe></figure><div class='iwantbar'>Watch more in <a href='//www.iwantv.com.ph/'>iWantv</a> or <a href='//tfc.tv/'>TFC.tv</a></div><p>MANILA - An official of the Research Institute for Tropical Medicine (RITM) who led a clinical trial of the controversial dengue vaccine Dengvaxia admitted Monday that she has a relative that works for drug maker Sanofi Pasteur.</p><p>The RITM in 2014 said their clinical trial for Dengvaxia showed "promising results," including a 56-percent reduction of dengue in 3,500 test subjects. Two years later, the Philippine government started administering the vaccine to thousands of public school children.</p><ul class='op-related-articles'>	<li><a href='http://news.abs-cbn.com/news/12/11/17/officials-defied-experts-advice-in-pursuing-dengue-immunization-program'>Officials defied experts' advice in pursuing dengue immunization program</a></li></ul><ul class='op-related-articles'>	<li><a href='http://news.abs-cbn.com/focus/12/13/17/did-sanofi-who-ignore-warning-signals-on-dengue-vaccine'>Did Sanofi, WHO ignore warning signals on dengue vaccine?</a></li></ul><p>The P3.5-billion project, however, was suspended last year after Sanofi disclosed that the vaccine could make the dengue worse if given to those who have not been infected with the mosquito-borne disease.</p><p>Dr. Rosario Capeding, principal investigator at the RITM, confirmed in a Senate hearing that Hazel Dy Tioco, director of clinical research operations at Sanofi-Asia Pacific, is her niece.<br/> <br/>Capeding rejected claims that her relationship with Dy Tioco marred the Dengvaxia trial study with conflict of interest.</p><p>"In terms of conflict of interest regarding blood relations in clinical trial, the requirement for a clinical trial staff is with regards to the education, training," she said.</p><p>"The conduct of clinical trial is regulated. There are independent clinical research organizations which monitor the conduct," she added.</p><p>Capeding said her niece was not involved with the procurement and licensing of Dengvaxia.</p><p>The 3,500 subject of the clinical trial, which was funded by Sanofi, remains "alive and well", except for one who died in a vehicular accident, she said.</p><figure class='op-interactive'><iframe allowfullscreen='' frameborder='0' height='315' src='https://www.youtube.com/embed/ylkNRyCiebc' width='560'></iframe></figure>

<ul class='op-related-articles'>	<li><a href='http://news.abs-cbn.com/news/12/11/17/officials-defied-experts-advice-in-pursuing-dengue-immunization-program'>Officials defied experts' advice in pursuing dengue immunization program</a></li></ul><ul class='op-related-articles'>	<li><a href='http://news.abs-cbn.com/focus/12/13/17/did-sanofi-who-ignore-warning-signals-on-dengue-vaccine'>Did Sanofi, WHO ignore warning signals on dengue vaccine?</a></li></ul><p>The P3.5-billion project, however, was suspended last year after Sanofi disclosed that the vaccine could make the dengue worse if given to those who have not been infected with the mosquito-borne disease.</p><p>Dr. Rosario Capeding, principal investigator at the RITM, confirmed in a Senate hearing that Hazel Dy Tioco, director of clinical research operations at Sanofi-Asia Pacific, is her niece.<br> <br>Capeding rejected claims that her relationship with Dy Tioco marred the Dengvaxia trial study with conflict of interest.</p><p>"In terms of conflict of interest regarding blood relations in clinical trial, the requirement for a clinical trial staff is with regards to the education, training," she said.</p><p>"The conduct of clinical trial is regulated. There are independent clinical research organizations which monitor the conduct," she added.</p><p>Capeding said her niece was not involved with the procurement and licensing of Dengvaxia.</p><p>The 3,500 subject of the clinical trial, which was funded by Sanofi, remains "alive and well", except for one who died in a vehicular accident, she said.</p><figure class='op-interactive'><iframe allowfullscreen='' frameborder='0' height='315' src='https://www.youtube.com/embed/ylkNRyCiebc' width='560'></iframe></figure>

<p>MANILA - An official of the Research Institute for Tropical Medicine (RITM) who led a clinical trial of the controversial dengue vaccine Dengvaxia admitted Monday that she has a relative that works for drug maker Sanofi Pasteur.</p><p>The RITM in 2014 said their clinical trial for Dengvaxia showed "promising results," including a 56-percent reduction of dengue in 3,500 test subjects. Two years later, the Philippine government started administering the vaccine to thousands of public school children.</p>

<figure class='op-interactive'><iframe height='315' src='https://www.youtube.com/embed/RU7FdPYTNyk?enablejsapi=1' width='560'></iframe></figure><div class='iwantbar'>Watch more in <a href='//www.iwantv.com.ph/'>iWantv</a> or <a href='//tfc.tv/'>TFC.tv</a></div>

<p>An official of the Research Institute for Tropical Medicine (RITM) who led a clinical trial of the controversial dengue vaccine Dengvaxia admitted Monday that she has a relative that works for drug maker Sanofi Pasteur.</p><p> </p>

An official of the Research Institute for Tropical Medicine (RITM) who led a clinical trial of the controversial dengue vaccine Dengvaxia admitted Monday that she has a relative that works for drug maker Sanofi Pasteur.

Head of Dengvaxia study admits she has relative in Sanofi | ABS-CBN News

News

News

Head of Dengvaxia study admits she has relative in Sanofi

Head of Dengvaxia study admits she has relative in Sanofi